Sichuan Biokin Stock Hits Day Low of CNY 254.90 Amid Price Pressure

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a notable decline in its stock performance today, with a decrease of 4.89% as of March 23, 2026. The stock reached an intraday low of CNY 254.90, reflecting ongoing volatility in the market. Over the past week, Sichuan Biokin has seen a decline of 2.75%, while its performance over the last month shows a more significant drop of 10.03%. In contrast, the China Shanghai Composite index has performed slightly better, with a weekly decline of 6.65% and a monthly decline of 6.58%. Despite a strong annual performance of 20.13%, the year-to-date figures reveal a challenging landscape for the company, with a decline of 20.09%. The company has reported negative results for the last four consecutive quarters, with net sales for the first nine months showing a significant decrease of 63.52%. Additionally, the net profit for the same period stands at a loss of CNY 500.37 million, marking a decline of 112.34%. Sichuan Biokin's market capitalization is currently CNY 29,530 million, positioning it within the large-cap segment of the pharmaceuticals and biotechnology industry.